Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;33(10):1029-1040.
doi: 10.1016/j.annonc.2022.07.005. Epub 2022 Jul 22.

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

B Ricciuti  1 , J V Alessi  1 , A Elkrief  2 , X Wang  3 , A Cortellini  4 , Y Y Li  5 , V R Vaz  1 , H Gupta  6 , F Pecci  1 , A Barrichello  1 , G Lamberti  1 , T Nguyen  1 , J Lindsay  7 , B Sharma  8 , K Felt  8 , S J Rodig  9 , M Nishino  10 , L M Sholl  11 , D A Barbie  1 , M V Negrao  12 , J Zhang  12 , A D Cherniack  6 , J V Heymach  12 , M Meyerson  6 , C Ambrogio  13 , P A Jänne  1 , K C Arbour  2 , D J Pinato  4 , F Skoulidis  12 , A J Schoenfeld  2 , M M Awad  1 , J Luo  14
Affiliations

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer

B Ricciuti et al. Ann Oncol. 2022 Oct.

Abstract

Background: Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous outcomes, driven by differences in underlying biology shaped by co-mutations. In contrast to KRASG12C NSCLC, KRASG12D NSCLC is associated with low/never-smoking status and is largely uncharacterized.

Patients and methods: Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype.

Results: Of 2327 patients with KRAS-mutated (KRASMUT) NSCLC, 15% (n = 354) harbored KRASG12D. Compared to KRASnon-G12D NSCLC, KRASG12D NSCLC had a lower pack-year (py) smoking history (median 22.5 py versus 30.0 py, P < 0.0001) and was enriched in never smokers (22% versus 5%, P < 0.0001). KRASG12D had lower PD-L1 tumor proportion score (TPS) (median 1% versus 5%, P < 0.01) and lower tumor mutation burden (TMB) compared to KRASnon-G12D (median 8.4 versus 9.9 mt/Mb, P < 0.0001). Of the samples which underwent multiplexed immunofluorescence, KRASG12D had lower intratumoral and total CD8+PD1+ T cells (P < 0.05). Among 850 patients with advanced KRASMUT NSCLC who received PD-(L)1-based therapies, KRASG12D was associated with a worse objective response rate (ORR) (15.8% versus 28.4%, P = 0.03), progression-free survival (PFS) [hazard ratio (HR) 1.51, 95% confidence interval (CI) 1.45-2.00, P = 0.003], and overall survival (OS; HR 1.45, 1.05-1.99, P = 0.02) to PD-(L)1 inhibition alone but not to chemo-immunotherapy combinations [ORR 30.6% versus 35.7%, P = 0.51; PFS HR 1.28 (95%CI 0.92-1.77), P = 0.13; OS HR 1.36 (95%CI 0.95-1.96), P = 0.09] compared to KRASnon-G12D.

Conclusions: KRASG12D lung cancers harbor distinct clinical, genomic, and immunologic features compared to other KRAS-mutated lung cancers and worse outcomes to PD-(L)1 blockade. Drug development for KRASG12D lung cancers will have to take these differences into account.

Keywords: G12D; KRAS; NSCLC; PD-(L)1 blockade.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Study cohorts and baseline clinicopathologic features of KRAS G12D and KRAS non-G12D NSCLC.
(A) The cohorts of patients included in this study. (B) The distribution of the most common KRAS mutations identified among NSCLCs at the DFCI, MSKCC, MDACC, and Imperial College (n = 2327). (C) Lollipop plot of the most common KRAS mutations identified at participating institutions (n = 2327). (D) The distribution of pack-years across the most common KRAS subtypes. (E) Distribution of metastatic sites in stage IV KRASG12D (n = 125) and KRASnon-G12D (n = 781) NSCLCs in the DFCI cohort. (F) PD-L1 TPS in KRASG12D NSCLC and KRASnon-G12D NSCLC. DFCI, Dana-Farber Cancer Institute; MDACC, MD Anderson Cancer Center; MSKCC, Memorial Sloan Kettering Cancer Center; NSCLC, non-small-cell lung cancer; PD-L1, programmed death-ligand 1; TPS, tumor proportion score.
Figure 2.
Figure 2.. Genomic profile of KRAS G12D NSCLC.
(A) Oncoprint of the top 20 genes altered in KRASG12D NSCLC. (B) Tumor mutational burden (TMB) in KRASG12D and KRASnon-G12D NSCLC. (C) Volcano plot showing oncogenic gene mutations-enriched KRASG12D versus KRASnon-G12D NSCLC. (D) Prevalence of oncogenic mutations significantly enriched in KRASG12D versus KRASnon-G12D NSCLC. NSCLC, non-small-cell lung cancer.
Figure 3.
Figure 3.. Immunophenotypic characteristics of KRAS G12D NSCLC.
(A, B) Representative multiplex immunofluorescence of a KRASG12D and a KRASnon-G12D (in this case, KRASG12C) NSCLC sample. Each image shown represents 925 μm × 693 μm from a single 20× region of interest. See Methods for additional details. (C) CD8+ T cells (D) PD-1+ cells, and (E) CD8+PD-1+ T cells in KRASG12D NSCLC (N = 24) versus KRASnon-G12D NSCLC (N = 116). (F) Proportion of PD-L1+ tumor, non-tumor, and total cells in NSCLCs with KRASG12D versus KRASnon-G12D mutations. Tumor–stroma interface (TSI) CD8+, PD-1+, and CD8+PD-1+ cells were examined in 16 KRASG12D and 68 KRASnon-G12D samples in which TSI was included in the biopsy. NSCLC, non-small-cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.
Figure 4.
Figure 4.. PD-L1 expression and TMB levels according to smoking status among KRAS G12D NSCLCs.
(A) Proportion of NSCLC samples with a PD-L1 TPS of <1%, 1%–49%, and ≥50%, in KRASG12D,light-sm (<10 pack-years smoking) and KRASG12D,heavy-sm (≥30 pack-years smoking) subsets. (B) TMB in KRASG12D,light-sm and KRASG12D,heavy-sm NSCLCs. NSCLC, non-small-cell lung cancer; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden; TPS, tumor proportion score.
Figure 5.
Figure 5.. Clinical outcomes to PD-(L)1 ± chemotherapy in patients with KRAS G12D versus KRAS non-G12D NSCLC.
(A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 blockade monotherapy in patients with advanced KRASG12D NSCLC versus KRASnon-G12D NSCLC. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 blockade therapy in combination with chemotherapy in advanced KRASG12D NSCLC versus KRASnon-G12D NSCLC. HR, hazard ratio; NSCLC, non-small-cell lung cancer; PD-L1, programmed death-ligand 1; PFS, progression-free survival; OS, overall survival.
See this image and copyright information in PMC

References

    1. Salgia R, Pharaon R, Mambetsariev I, Nam A, Sattler M. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Rep Med. 2021;2:100186. - PMC - PubMed
    1. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS p. G12C mutation. N Engl J Med. 2021;384:2371–2381. - PMC - PubMed
    1. Riely GJ, Ou SHI, Rybin I, et al. 99O_PR KRYSTAL-1: activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation. J Thorac Oncol. 2021;16:S751–S752.
    1. Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a non-covalent, potent, and selective KRAS G12D inhibitor. J Med Chem. 2022;65:3123–3133. - PubMed
    1. Hood FE, Klinger B, Newlaczyl AU, et al. Isoform-specific Ras signaling is growth factor dependent. Mol Biol Cell. 2019;30:1108–1117. - PMC - PubMed

Publication types

MeSH terms

Substances